About Telavant
Telavant is a company based in New York (United States) founded in 2022 was acquired by Roche in October 2023. Telavant offers products and services including Susvimo and Diagnostic Solutions. Telavant operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name F. Hoffmann-La Roche Ltd
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Telavant
Telavant offers a comprehensive portfolio of products and services, including Susvimo and Diagnostic Solutions.
Treatment for diabetic macular edema via continuous delivery.
Products for accurate disease diagnosis and patient stratification.
Funding Insights of Telavant
Detailed funding history for Telavant
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Telavant
Telavant has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals and diagnostics kits are developed for various diseases.
|
Locked | Locked | Locked |
Investor details for Telavant
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Telavant
Investment portfolio details for Telavant
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Telavant
Detailed financials for Telavant
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Telavant Comparisons
Peer comparison for Telavant
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Telavant
Telavant operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Telavant
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Telavant
Complete news archive for Telavant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Telavant
Telavant was founded in 2022.
Telavant is headquartered in New York, United States. It is registered at New York, New York, United States.
Frank Torti is the current CEO of Telavant.
Telavant was founded in 2022 and is headquartered in New York, United States. Focus is placed on the biotechnology sector, where therapeutics targeting inflammatory and fibrotic conditions are developed. Operations center on advancing biologic candidates, including the lead asset RVT-3101, a human monoclonal antibody directed at TL1A. This therapy is formulated for subcutaneous administration to address ulcerative colitis and Crohns disease in patients.
Telavant's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Telavant offers Susvimo and Diagnostic Solutions.
Telavant has 1 investor. Key investors include Roche.